-
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for the first six months of the year. The firm reported RMB 1.464 billion ($204.3 million) in revenues, down 23.2% year-on-year (YOY). The decline was attributed to COVID-19 related lockdowns in the domestic market. Business Segment…
-
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
•
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng’s paclitaxel for injection (albumin-bound, 100mg/vial) in the US market. Meitheal will…
-
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
•
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a patent dispute with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) over the multiple sclerosis blockbuster drug Gilenya (fingolimod). In January 2022, the US Court of Appeals for the Federal Circuit (CAFC) had dismissed an appeal…
-
Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293
•
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI under a deal that closed in 2018, has unveiled a collaboration and licensing deal with Germany-based Merck Healthcare KGaA. The agreement grants Merck global rights to develop and commercialize the poly (ADP-ribose) polymerase 1 (PARP1)…
-
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
•
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been reported as saying that the company is “eager” to bring its mRNA-based COVID-19 vaccines to China. According to sources, Moderna’s chief executive Stephane Bancel disclosed last week that the company has engaged in talks with…
-
Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya
•
Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback in the fight to maintain a key patent covering the multiple sclerosis drug Gilenya (fingolimod) in the United States. The company announced that the US Court of Appeals for the Federal Circuit (CAFC) had denied…
-
Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), has entered into a licensing agreement with France-headquartered Inventiva (NASDAQ: IVA). The deal grants CTTQ development, manufacturing, and commercialization rights to lanifibranor, Inventiva’s drug for the treatment of nonalcoholic steatohepatitis (NASH)…
-
Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review
•
China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276) dexmedetomidine hydrochloride nasal spray has been awarded priority review status. The drug is filed for approval as a preoperative sedation in children, such as for general anesthesia in pediatric patients. Drug Overview and Market ContextDexmedetomidine,…
-
Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform
•
Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to co-develop a pan-cancer single-cell molecular diagnostic innovation platform. The collaboration leverages the respective platform advantages and integrates resources to work on a single-cell clinical molecular diagnosis project based on high-throughput next-generation sequencing technology. Moving forward,…
-
Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions
•
Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.…
-
InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade
•
China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) at RMB 11.03 per share ($1.55). The offering raised RMB 2.92 billion ($411 million), with proceeds allocated towards new drug research and development (R&D), upgrading…
-
Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China
•
China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has been approved by the National Medical Products Administration (NMPA) for use as a combination therapy for seizures in patients with Lennox-Gastaut syndrome (LGS) aged two years and older. This marks the first availability of this…
-
AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion
•
China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71 million shares to the Hong Kong Stock Exchange at HKD 16.16 ($2.06) per share on October 6, 2022. The proceeds from the HKD 181 million ($23 million) IPO will be used to fund vaccine research…
-
AstraZeneca and Merck’s Lynparza Receives New Approval in China
•
UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced that they have received another indication approval from the National Medical Products Administration (NMPA) for Lynparza (olaparib). The poly (ADP-ribose) polymerase (PARP) inhibitor is now approved as a maintenance therapy for homologous recombination repair deficiency…
-
Shandong Luoxin Partners with Shanghai Pharma for Strategic Services
•
China-based Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793) has announced a partnership with compatriot firm Shanghai Pharmaceutical Co., Ltd. Under the agreement, Shanghai Pharma will become Luoxin’s strategic partner in China, providing a range of services including end delivery and marketing, import and export supply chain management, branding…
-
Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Janus kinase (JAK) inhibitor, jacktinib, in systemic lupus erythematosus (SLE). This marks a significant milestone in the development of this innovative therapy for autoimmune diseases.…
-
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
•
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that the deadline for its proposed takeover by Sino Biopharmaceutical Ltd (HKG: 1177) subsidiary invoX Pharma has been delayed for a second time. The delay is attributed to a review by the Committee on Foreign Investment…
-
Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine
•
Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round solely led by Brain Venture Capital. The proceeds will be directed towards medical device research and development, pre-clinical studies, and clinical trial filings. The Guangming Brain Science Technology Industry Innovation Center will provide NeuroPlus with…
-
Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center
•
German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of the first phase of a new EUR 29 million ($28.5 million) China Biologics Testing Center in Shanghai. The 5,000 square meter center is the first of its kind for Merck in China and is designed…
-
METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program
•
Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi Inc. to secure exclusive global development and commercialization rights to Voronoi’s pan-RAF inhibitor program. The deal involves an upfront payment of $1.7 million and up to $480.5 million in development, regulatory, and sales milestones, as…
